Tetanus Shot Ups Survival With Brain Tumor Immunotherapy

This article originally appeared here.
Share this content:
Tetanus Shot Ups Survival With Brain Tumor Immunotherapy
Tetanus Shot Ups Survival With Brain Tumor Immunotherapy

FRIDAY, March 13, 2015 (HealthDay News) -- Adding a simple tetanus shot to dendritic cell immunotherapy for glioblastoma dramatically extended some patients' survival in a small new study. The study was published online March 11 in Nature.

Kristen Batich, a dual medical-doctoral degree student at Duke University in Durham, N.C., and colleagues split 12 glioblastoma patients into two groups: six received a tetanus booster and six received a placebo. The following day, all 12 patients underwent dendritic cell immunotherapy. In this case, the Duke team extracted patients' white blood cells, coaxed the growth of dendritic cells, and loaded them with an antigen targeting the cytomegalovirus in glioblastoma tumors. The dendritic cell vaccine was then injected back into the cancer patients. The purpose was to signal lymph nodes to search and attack the cytomegalovirus-laden tumor.

Even in the non-tetanus shot group, survival times were somewhat longer than average for glioblastoma patients. Half of those patients lived about 18.5 months from diagnosis, the researchers said. Three of the six patients randomly selected to receive a tetanus shot plus dendritic cell therapy were alive at the time of researchers' survival analysis. One lived 4.8 years, while another lived 5.9 years, and the remaining patient continues to have no tumor growth 8.8 years after treatment.

"Because the [average] survival is 12 to 15 months in patients who receive a diagnosis of this tumor, we were quite surprised by the results of three patients who had much longer survival times," Batich told HealthDay.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »